tested by Reverse Phase Protein Array (RPPA) for the expression levels of 300 proteins. Ingenuity Pathway Analysis (IPA) of 64 proteins (grey circles) differentially expressed between the combination and single agents revealed reduction in the expression levels of mTOR related proteins (red circles). (B) Graphical representation of the changes in the expression levels of the mTOR related proteins (red circles in Figure 3A ) by selinexor and DEX alone or in combination compared to the DMSO treated sample. . Mice were treated with vehicle or 15 mg/kg of selinexor for 18 days. Selinexor was given via oral gavage on a Monday-Wednesday-Friday schedule (MWF). The group that received vehicle exhibited basal levels of GR expression when compared to the selienxor treated group, which exhibited an induction of GR expression levels. 2 × 10 4 MM.1S cells/well in a 96-well plate were treated with various concentrations of selinexor, and DEX and incubated at 37°C in a 5% humidified CO 2 incubator for 72 hours. Cell viability was determined using CellTiter-Fluor Viability Assay (Promega#G6082) and Caspase 3/7 Glo Viability Assay (Promega#G8092) per the manufacturer's instructions. CI values were calculated using CI software. The values obtained show that selinexor and dexamethasome synergize to induce cell death at most of the concentrations tested. 4 H929 cells/well in a 96-well plate were treated with various concentrations of selinexor, and DEX and incubated at 37°C in a 5% humidified CO 2 incubator for 72 hours. Cell viability was determined using CellTiter-Fluor Viability Assay (Promega#G6082) and Caspase 3/7 Glo Viability Assay (Promega#G8092) per the manufacturer's instructions. CI values were calculated using Compusyn software. Although H929 cells are somewhat resistant to dexamethasome as a single agent, the values obtained show that selinexor and dexamethasome synergize to induce cell death.
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